NASDAQ: BMEA
BMF-219 is an investigational novel covalent menin inhibitor designed to regenerate insulin-producing beta cells with the aim to cure type 2 diabetes
- An abstract, “BMF-219: A novel therapeutic agent to reestablish functional beta cells and provide long-term glycemic control” will be presented during the WCIRDC meeting held in Los Angeles, December 7-9, 2023
- Additionally, Biomea will hold new investigator educational meeting during WCIRDC to discuss the role of menin as a regulator of glycemic control and beta-cell mass, and to illustrate the mechanism of action of BMF-219, highlighting new clinical data from COVALENT-111
- Topline data of the escalation portion of COVALENT-111 will be announced in December